| 32.59 -0.67 (-2.01%) | 11-07 10:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.89 | 1-year : | 43.74 |
| Resists | First : | 35.01 | Second : | 37.45 |
| Pivot price | 34 |
|||
| Supports | First : | 31.06 | Second : | 25.85 |
| MAs | MA(5) : | 33.5 |
MA(20) : | 34.15 |
| MA(100) : | 33.71 |
MA(250) : | 34.29  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.8 |
D(3) : | 45.9 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 46.47 | Low : | 25.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TGTX ] has closed above bottom band by 4.0%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 34.16 - 34.34 | 34.34 - 34.49 |
| Low: | 32.4 - 32.6 | 32.6 - 32.77 |
| Close: | 32.93 - 33.27 | 33.27 - 33.56 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Wed, 05 Nov 2025
The Bull Case For TG Therapeutics (TGTX) Could Change Following Raised 2025 Outlook and Surging BRIUMVI Sales - simplywall.st
Tue, 04 Nov 2025
TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2025 Earnings Call Transcript - Insider Monkey
Tue, 04 Nov 2025
TG Therapeutics: Q3 Earnings Snapshot - theheraldreview.com
Tue, 04 Nov 2025
TG Therapeutics: Q3 Earnings Snapshot - CT Insider
Mon, 03 Nov 2025
TG Therapeutics Inc (TGTX) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... - Yahoo Finance
Mon, 03 Nov 2025
TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows (NASDAQ:TGTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 159 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 9.7 (%) |
| Held by Institutions | 64.3 (%) |
| Shares Short | 23,810 (K) |
| Shares Short P.Month | 24,590 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.89 |
| Profit Margin | 13.3 % |
| Operating Margin | 24.6 % |
| Return on Assets (ttm) | 9.7 % |
| Return on Equity (ttm) | 26.6 % |
| Qtrly Rev. Growth | 92 % |
| Gross Profit (p.s.) | 2.48 |
| Sales Per Share | 2.86 |
| EBITDA (p.s.) | 0.54 |
| Qtrly Earnings Growth | 325 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | 86.15 |
| PEG Ratio | 0 |
| Price to Book value | 17.23 |
| Price to Sales | 11.44 |
| Price to Cash Flow | -87.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|